title: Immunospecific reduction of antioligonucleotide antibody-forming cells with a tetrakis-oligonucleotide conjugate (LJP 394), a therapeutic candidate for the treatment of lupus nephritis.
abstract: A discrete tetravalent conjugate, 7a (LJP 394), consisting of four oligonucleotides attached to a common carrier or platform was prepared. Single-stranded oligonucleotide 20-mers consisting of alternating deoxycytidine-deoxyadenosine nucleotides, (CA)10, were attached to a tetrabromoacetylated platform by displacement with sulfhydryl-terminated linkers. The tetrabromoacetylated platform 3a was synthesized in three steps using triethylene glycol bis-(chloroformate). The single-stranded conjugate was characterized by polyacrylamide gel electrophoresis, DNA sequencing, phosphate analysis, carbon and nitrogen combustion analysis, and correlation of stoichiometry to conversion in the conjugation process. HPLC and capillary electrophoretic methods were developed to evaluate purity. The tetrakis, single-stranded conjugate was annealed with a stoichiometric amount of a complementary single-stranded oligonucleotide 20-mer consisting of alternating thymidine-deoxyguanosine nucleotides, (TG)10. The double-stranded conjugate LJP 394 was characterized by melt temperature and hyperchromicity, phosphate analysis, and carbon and nitrogen combustion analysis. LJP 394 inhibits binding of DNA to anti-double-stranded oligonucleotide antibodies and reduces anti-oligonucleotide-specific plaque (antibody)-forming cells in an immunized mouse model by a proposed mechanism involving cross-linking B cell surface immunoglobins.
authors.affiliation: La Jolla Pharmaceutical Company, San Diego, California 92121, USA.
authors.forename: D S
authors.initials: DS
authors.lastname: Jones
authors.forename: P A
authors.initials: PA
authors.lastname: Barstad
authors.forename: M J
authors.initials: MJ
authors.lastname: Feild
authors.forename: J P
authors.initials: JP
authors.lastname: Hachmann
authors.forename: M S
authors.initials: MS
authors.lastname: Hayag
authors.forename: K W
authors.initials: KW
authors.lastname: Hill
authors.forename: G M
authors.initials: GM
authors.lastname: Iverson
authors.forename: D A
authors.initials: DA
authors.lastname: Livingston
authors.forename: M S
authors.initials: MS
authors.lastname: Palanki
authors.forename: A R
authors.initials: AR
authors.lastname: Tibbetts
mesh_terms: D000818:Animals; D000921:Antibody-Producing Cells / Q000187:drug effects* / Q000276:immunology; D004195:Disease Models, Animal; D005260:Female; D006462:Hemolytic Plaque Technique; D006801:Humans; D008181:Lupus Nephritis / Q000188:drug therapy* / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D009841:Oligonucleotides / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D013154:Spleen / Q000187:drug effects / Q000276:immunology / Q000473:pathology
chemical_list: D009841:Oligonucleotides; C094104:abetimus